Indaptus Clears Next Step in Decoy20 Phase 1 Trial for Cancer Treatment

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotech company focused on developing novel treatments for cancer and viral infections, has provided an update on key clinical progress in its Phase 1 trial of lead drug candidate Decoy20.

The Safety Review Committee has reviewed data from weekly administrations at the lower dose of Decoy20 and approved the unrestricted enrollment of patients at this dose. So far, the safety profile is consistent with the drug’s expected mechanism of action, with notable treatment-related adverse events being Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both of which were transient.

Dr. Roger Waltzman, Indaptus’ Chief Medical Officer, stated that unrestricted enrollment at the lower dose will help gather more safety and efficacy data, which is vital for assessing Decoy20’s full potential. This data will also guide plans for initiating combination therapy next year, a critical step in advancing the drug.

Chief Executive Officer Jeffrey Meckler emphasized that the data collected so far aligns with preclinical expectations, and that the trial's continuation, along with future combination therapy studies, represents a significant opportunity to advance cancer immunotherapy. The company expects to share more results in the coming months.